Reference : Effect of a sequential treatment combining abaloparatide and alendronate for the mana...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/223121
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis
English
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Al-Daghri, Nasser [Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique >]
Kaufman, Jean-Marc [Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique >]
Bruyère, Olivier mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
2017
Expert Opinion on Pharmacotherapy
Taylor and Francis Ltd
1-3
Yes (verified by ORBi)
International
1465-6566
1744-7666
[en] Abaloparatide ; osteoporosis ; bisphosphonates ; sequential treatment ; fractures
[en] The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 µg/day) (ABL) for 18 months followed by 6 months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with an osteoanabolic agent. The ABL/ALN sequence resulted in greater bone mineral density gains at all skeletal sites and in a reduction of vertebral, non-vertebral, major and clinical fractures compared to what is observed after 18 months of placebo followed by 6 months of ALN. Whereas questions remained unanswered about the ideal anti-resorptive agent to be used after ABL, the optimal duration of the administration of the anti-resorptive drug or the potential interest of re-initiating a course of ABL after a limited administration of ALN, these results support the use of the ABL/ALN sequence in the management of postmenopausal osteoporosis. © 2017 Informa UK Limited, trading as Taylor & Francis Group
http://hdl.handle.net/2268/223121
10.1080/14656566.2017.1418857

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Effect of sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.pdfPublisher postprint583.97 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.